Correction to: Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart (Circulation Research (2013) 112 (289-297) DOI: 10.1161/CIRCRESAHA.111.300003);Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium atpase type 2a Signaling complexes in mouse heart

Circulation Research

Volumn 112, Issue 2, 2013, Pages 289-297

  Beca, Sanja ^c   Ahmad, Faiyaz ^a   Shen, Weixing ^a   Liu, Jie ^b,c   Makary, Samy ^c,e   Polidovitch, Nazari ^c   Sun, Junhui ^a   Hockman, Steven ^a   Chung, Youn Wook ^a   Movsesian, Matthew ^f   Murphy, Elizabeth ^a   Manganiello, Vincent ^a   Backx, Peter H ^c,d,e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d Mathematics and Computer Science   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

calcium regulation; cAMP; contractility; phosphodiesterase type 3A knock out mice; sarcoplasmic reticulum calcium ATPase type 2a

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 18; PHOSPHODIESTERASE 3A; PHOSPHODIESTERASE 3B; PHOSPHODIESTERASE III; PHOSPHOLAMBAN; PHOSPHOPROTEIN PHOSPHATASE 2A; SARCOPLASMIC RETICULUM CALCIUM ADENOSINE TRIPHOSPHATASE 2A; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG;

AMPLITUDE MODULATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVITY; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HEART RATE; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 84872847888     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/RES.0000000000000234     Document Type: Erratum

References (44)

1. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415:198-205.
2. Michel JJ, Scott JD. AKAP mediated signal transduction. Annu Rev Pharmacol Toxicol. 2002;42:235-257.
3. Steinberg SF, Brunton LL. Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. Annu Rev Pharmacol Toxicol. 2001;41:751-773.
4. Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res. 2007;100:1569-1578.
5. Patrucco E, Albergine MS, Santana LF, Beavo JA. Phosphodiesterase 8A (PDE8A) regulates excitation-contraction coupling in ventricular myocytes. J Mol Cell Cardiol. 2010;49:330-333.
6. Osadchii OE. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. Cardiovasc Drugs Ther. 2007;21:171-194.
7. Kerfant BG, Gidrewicz D, Sun H, Oudit GY, Penninger JM, Backx PH. Cardiac sarcoplasmic reticulum calcium release and load are enhanced by subcellular cAMP elevations in PI3Kgamma-deficient mice. Circ Res. 2005;96:1079-1086.
8. Kerfant BG, Rose RA, Sun H, Backx PH. Phosphoinositide 3-kinase gamma regulates cardiac contractility by locally controlling cyclic adenosine monophosphate levels. Trends Cardiovasc Med. 2006;16:250-256.
9. Kerfant BG, Zhao D, Lorenzen-Schmidt I, Wilson LS, Cai S, Chen SR, Maurice DH, Backx PH. PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes. Circ Res. 2007;101:400-408.
10. Colucci WS. Cardiovascular effects of milrinone. Am Heart J. 1991;121:1945-1947.
11. +) uptake function of cardiac sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol. 2000;279:H1898-H1905.
12. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol. 2003;4:566-577.
13. Rochais F, Abi-Gerges A, Horner K, Lefebvre F, Cooper DM, Conti M, Fischmeister R, Vandecasteele G. A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes. Circ Res. 2006;98:1081-1088.
14. + re-uptake into heart sarcoplasmic reticulum. EMBO Rep. 2007;8:1061-1067.
15. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325:1468-1475.
16. Movsesian M, Stehlik J, Vandeput F, Bristow MR. Phosphodiesterase inhibition in heart failure. Heart Fail Rev. 2009;14:255-263.
17. Mangiafico RA, Fiore CE. Current management of intermittent claudication: the role of pharmacological and nonpharmacological symptomdirected therapies. Curr Vasc Pharmacol. 2009;7:394-413.
18. Sun B, Li H, Shakur Y, Hensley J, Hockman S, Kambayashi J, Manganiello VC, Liu Y. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell Signal. 2007;19:1765-1771.
19. Patrucco E, Notte A, Barberis L, et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and-independent effects. Cell. 2004;118:375-387.
20. Masciarelli S, Horner K, Liu C, Park SH, Hinckley M, Hockman S, Nedachi T, Jin C, Conti M, Manganiello V. Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. J Clin Invest. 2004;114:196-205.
21. Choi YH, Park S, Hockman S, et al. Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice. J Clin Invest. 2006;116:3240-3251.
22. Sutherland FJ, Shattock MJ, Baker KE, Hearse DJ. Mouse isolated perfused heart: characteristics and cautions. Clin Exp Pharmacol Physiol. 2003;30:867-878.
23. Endoh M, Hori M. Acute heart failure: inotropic agents and their clinical uses. Expert Opin Pharmacother. 2006;7:2179-2202.
24. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J. 2003;370:1-18.
25. De Arcangelis V, Soto D, Xiang Y. Phosphodiesterase 4 and phosphatase 2A differentially regulate cAMP/protein kinase a signaling for cardiac myocyte contraction under stimulation of beta1 adrenergic receptor. Mol Pharmacol. 2008;74:1453-1462.
26. + current trigger. J Physiol (Lond). 2004;556:463-480.
27. +) release in cardiac myocytes by changes in repolarization rate: role of phase-1 action potential repolarization in excitation-contraction coupling. Circ Res. 2002;90:165-173.
28. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol. 2001;2:599-609.
29. Wuytack F, Raeymaekers L, Missiaen L. Molecular physiology of the SERCA and SPCA pumps. Cell Calcium. 2002;32:279-305.
30. Lowes BD, Simon MA, Tsvetkova TO, Bristow MR. Inotropes in the beta-blocker era. Clin Cardiol. 2000;23:III11-III16.
31. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, Ferguson DA, Bristow MR. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol. 1998;31:1336-1340.
32. Reinhardt RR, Chin E, Zhou J, Taira M, Murata T, Manganiello VC, Bondy CA. Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J Clin Invest. 1995;95:1528-1538.
33. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, Elbatarny HS, Jimmo SL. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol. 2003;64:533-546.
34. Bridge JH, Savio-Galimberti E. What are the consequences of phosphorylation and hyperphosphorylation of ryanodine receptors in normal and failing heart? Circ Res. 2008;102:995-997.
35. Georget M, Mateo P, Vandecasteele G, Lipskaia L, Defer N, Hanoune J, Hoerter J, Lugnier C, Fischmeister R. Cyclic AMP compartmentation due to increased cAMP-phosphodiesterase activity in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8). FASEB J. 2003;17:1380-1391.
36. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, Huston E, Hannawacker A, Lohse MJ, Pozzan T, Houslay MD, Zaccolo M. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res. 2004;95:67-75.
37. Houslay MD. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci. 2010;35:91-100.
38. Shan J, Betzenhauser MJ, Kushnir A, Reiken S, Meli AC, Wronska A, Dura M, Chen BX, Marks AR. Role of chronic ryanodine receptor phosphorylation in heart failure and β-adrenergic receptor blockade in mice. J Clin Invest. 2010;120:4375-4387.
39. Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD, Richter W, Jin SL, Conti M, Marks AR. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell. 2005;123:25-35.
40. Yan C, Miller CL, Abe J. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res. 2007;100:489-501.
41. Yan C, Ding B, Shishido T, Woo CH, Itoh S, Jeon KI, Liu W, Xu H, McClain C, Molina CA, Blaxall BC, Abe J. Activation of extracellular signal-regulated kinase 5 reduces cardiac apoptosis and dysfunction via inhibition of a phosphodiesterase 3A/inducible cAMP early repressor feedback loop. Circ Res. 2007;100:510-519.
42. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res. 2007;100:309-327.
43. Pokreisz P, Vandenwijngaert S, Bito V, et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation. 2009;119:408-416.
44. Miller CL, Yan C. Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications. J Cardiovasc Transl Res. 2010;3:507-515.